Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b2 bivalent (wildtype and Omicron BA.1)
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
BNT162b2 bivalent (wildtype and Omicron BA.1) is a nucleoside-modified messenger RNA (modRNA) vaccine developed by Pfizer and BioNTech, evaluated in clinical trials sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). This bivalent formulation contains two mRNA components: one encoding the spike glycoprotein of the ancestral (wild-type) SARS-CoV-2 strain and another encoding the spike glycoprotein of the Omicron BA.1 variant (B.1.1.529). Formulated in lipid nanoparticles (LNPs), the vaccine works by delivering mRNA into host cells, which then produce the stabilized prefusion spike proteins. This process elicits a broad immune response, including neutralizing antibodies and cellular immunity, intended to provide enhanced protection against emerging variants.
- Brand names
- Comirnaty Original/Omicron BA.1
- Other names
- BNT162b2 bivalent (wildtype and Omicron BA.1)Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.1)BNT162b2 (B.1.1.529) bivalent
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on BNT162b2 bivalent (wildtype and Omicron BA.1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b2 bivalent (wildtype and Omicron BA.1).